DIA Biosimilars 2013

Bill & Melinda Gates Foundation

Global Health Investment Fund launched for late-stage vaccines

Friday, September 27, 2013 10:59 AM

A new investment fund structured by JPMorgan Chase and the Bill & Melinda Gates Foundation will, for the first time, allow individual and institutional investors the opportunity to finance late-stage global health technologies that have the potential to save millions of lives in low-income countries.

More... »

Cenduit: Now with Patient Reminders

Japan screening massive drug compound libraries for new treatments

Wednesday, June 5, 2013 01:32 PM

The Global Health Innovative Technology Fund (GHIT Fund), a public-private partnership focused on Japanese R&D related to infectious disease, will make a series of agreements to screen compound libraries at Japanese pharmaceutical companies and research institutes for new treatments for malaria, tuberculosis and other afflictions.

More... »

CRF Health – eCOA Forum

Japan establishes global fund for R&D of new medicines, vaccines, diagnostics

Wednesday, April 10, 2013 10:15 AM

Japan’s first public-private partnership to advance the development of new health technologies for the developing world The Global Health Innovative Technology Fund (GHIT Fund) has officially launched. The GHIT Fund has been established to advance the R&D of new medicines, vaccines and diagnostics to fight infectious diseases in the developing world.

More... »

Atreca receives $6M for Immune Repertoire Capture tech for infectious diseases

Friday, September 28, 2012 11:47 AM

Atreca, a privately held biopharmaceutical company based in San Carlos, Calif., has formed a collaboration with the Bill & Melinda Gates Foundation to accelerate the discovery and development of novel vaccines and therapeutics for human infectious diseases.

More... »

Emory to receive $6 million for AIDS vaccine research

Friday, September 21, 2012 11:04 AM

A team of researchers at Emory University has received a three-year grant of $6 million from the Bill & Melinda Gates Foundation as part of the Collaboration for AIDS Vaccine Discovery (CAVD), an international network of scientists and experts dedicated to developing an effective vaccine for HIV/AIDS.

More... »

First vaccine for fatal visceral leishmaniasis enters clinical trial

Monday, February 27, 2012 10:08 AM

Seattle-based nonprofit Infectious Disease Research Institute (IDRI) has teamed up with India-based Gennova Biopharmaceuticals to target visceral leishmaniasis (VL), launching a phase I trial of vaccine for the infection disease.

More... »

International collaboration to combat 10 neglected tropical diseases by 2020

Monday, January 30, 2012 03:49 PM

Thirteen pharmaceutical companies, the U.S., U.K. and U.A.E governments, the Bill & Melinda Gates Foundation, the World Bank and other global health organizations will join forces to eliminate or control 10 neglected tropical diseases (NTDs) by the end of the decade.

More... »

GVK partners with Gates Foundation

Monday, May 16, 2011 12:44 PM

India-based CRO GVK Biosciences has been named as a preferred provider by a consortium, Product Development Partners (PDP), which is focused on drugs for neglected diseases.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs